Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or California for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to California only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. California (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Sarju Patel (NPI 1730384876)

Field	Value
Entity Type	Individual
Organization	Sarju Patel
Address	3939 J St
City	Sacramento
State	CA
ZIP	95819
Taxonomy	Uveitis and Ocular Inflammatory Disease (Ophthalmology) Physician
NPI Enumerated	June 19, 2007

Payer Source	Total Paid
Medicare	$7.5M
Medicaid	$0

Key Findings

This provider is effectively single‑payer in scope: lifetime Medicare revenue is $7.5M and there is none in Medicaid billing on file, so Medicare activities drive all documented public‑payer revenue and payer‑mix analysis should treat this as a Medicare-centric practice. The absence of Medicaid billing may reflect the provider’s patient population, payer contracting choices, or site-of-service mix rather than lack of clinical activity.

Revenue concentration is pronounced: the precomputed top 3 Medicare codes by revenue account for 76.3% of this provider's total Medicare revenue, driven primarily by J0178 ($3.7M, 49.8%), J2777 ($1.3M, 17.9%), and Q5124 ($644.7K, 8.6%). This concentration indicates most Medicare dollars come from intravitreal pharmaceutical administration rather than from broad outpatient evaluation codes.

The code mix indicates an injection‑centric retinal practice: the three largest revenue contributors are J0178, J2777, and Q5124 (all intravitreal biologic/drug administration), and the provider also reports high volumes of retina imaging and injection procedure codes such as 92134 (5.7K claims, $181.8K) and 67028 (4K claims, $414.9K). Together these claims and codes are consistent with a service model focused on chronic retinal disease management (repeat injections plus frequent imaging and follow‑up).

J0178 is an outsized national performer for this provider: it generated $3.7M (49.8% of Medicare revenue) and ranks #22 of 3204 providers nationally (99th percentile; extreme outlier). This rank identifies the provider as a national high‑volume deliverer of that specific drug administration relative to peers and suggests operational capacity and referral patterns centered on aflibercept injections.

Several procedure and E/M codes also appear as statistical outliers, signaling unusually high procedural throughput: 92134 ranks #18 of 26868 (100th percentile; extreme outlier) with 5.7K claims, 67028 ranks #30 of 4255 (99th percentile; extreme outlier) with 4K claims, and 92012/92014 show elevated ranks as well. These high percentiles across both imaging and injection procedure codes point to a high‑volume retina clinic rather than a primarily consultative or low‑volume surgical practice.

While J2777 shows very high claim count (46K claims) and meaningful revenue ($1.3M, 17.9%), its average paid/claim ($29) is low compared with J0178’s $691; the provider’s portfolio includes multiple injection codes (including Q5124, Q5128, J2778, J2781) and unclassified/compounded drug entries (J3490, J7999), indicating use of a mix of branded, biosimilar, and compounded therapies that diversify clinical offerings within the retinal injection line.

The provider’s long tenure is notable: NPI enumerated 2007-06-19 (~19 years ago), which supports an established referral base and operational infrastructure consistent with the observed high procedure volumes. Longevity combined with concentrated injection revenue suggests sustained specialization in retinal disease management.

From a business risk and competitive perspective, the heavy reliance on a very small set of high‑revenue intravitreal drug codes (top 3 = 76.3%) creates sensitivity to drug‑specific reimbursement changes or shifts in therapeutic patterns; coupled with no Medicaid revenue, any payer mix or reimbursement disruption in Medicare could materially affect this provider’s public‑payer revenue stream. Analysts should prioritize monitoring reimbursement trends for J0178, J2777, and Q5124 and assess how biosimilar adoption or new agents could alter utilization and average paid/claim dynamics.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

33 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J0178	Injection, aflibercept, 1 mg	5,380	$690	$3.7M
J2777	Injection, faricimab‑svoa, 0.1 mg	45,960	$30	$1.3M
Q5124	Injection, ranibizumab-nuna, biosimilar, (byooviz), 0.1 mg	3,770	$170	$644.7K
67028	The provider injects a medication into the vitreous chamber of the eye as an isolated procedure or a separate procedure unrelated to any other procedure being performed on the eye.	3,950	$110	$414.9K
J3490	Unclassified drugs	110	$2,000	$222.4K
92014	An ophthalmologist sees an established patient for a comprehensive level eye examination. Generally, a patient is considered to be "established" if the same physician, or any physician in the group…	2,130	$100	$204.5K
92134	The provider performs computerized diagnostic imaging of the retina in the posterior segment (back part) of the eye, interprets the data, and provides a report. The service may be on one or both eyes.	5,680	$30	$181.8K
J2778	Injection, ranibizumab, 0.1 mg	740	$180	$135.4K
92012	For this CPT code, an Ophthalmologist sees an established patient for an intermediate level eye examination. Generally, a patient is considered to be "established" if the same physician, or any…	1,340	$70	$97.7K
92235	The provider uses a special dye, fluorescein that causes the blood vessels in the one or both eyes to stand out in photographic images taken with the use of multiframe timing, or serial images, taken…	640	$110	$71.7K

Showing 1–10 of 33

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 33 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. California Distribution

Sarju Patel — 9 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — California

Full comparison — all codes billed, vs. state median

33 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J0178	2	310	570	$690	$647.1K
J2777	10	200	10,740	$30	$459.5K
Q5128	37	50	800	$220	$286.7K
Q5124	3	30	810	$170	$217.3K
J2778	63	130	700	$180	$196K
J2781	33	60	480	$120	$95.7K
67210	12	50	40	$450	$74.2K
67028	4	470	420	$100	$71.8K
J3490	130	320	80	$190	$49.2K
J7312	10	40	240	$160	$40.5K

Showing 1–10 of 33

Related Providers

Other providers that share a Tax Identification Number (TIN) with Sarju Patel, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Louis Chang	CA	Ophthalmology Physician	$2.2M	$5.9M
Nosheen Khan	NY	Podiatrist	$7.7M	$0
Alok Bansal	CA	Ophthalmology Physician	$3M	$4.7M
Carlos Medina Mendez	CA	Retina Specialist (Ophthalmology) Physician	$6M	$0
Inder Singh	CA	Interventional Cardiology Physician	$4.7M	$0
Robert Wendel	CA	Retina Specialist (Ophthalmology) Physician	$4.7M	$0
Roger Goldberg	CA	Retina Specialist (Ophthalmology) Physician	$4.6M	$0
James Joye	CA	Interventional Cardiology Physician	$4.5M	$0
Cameron Pole	CA	Ophthalmology Physician	$4.5M	$0
Margaret Chang	CA	Retina Specialist (Ophthalmology) Physician	$4.3M	$0

Nearby Providers

Other providers in the same ZIP code as Sarju Patel, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Dignity Health	CA	General Acute Care Hospital	$0	$45.5M
Tony Tsai	CA	Retina Specialist (Ophthalmology) Physician	$3.9M	$0
David Cupp	CA	Retina Specialist (Ophthalmology) Physician	$3.8M	$0
David Telander	CA	Retina Specialist (Ophthalmology) Physician	$3.6M	$0
Joel Pearlman	CA	Retina Specialist (Ophthalmology) Physician	$3.3M	$0
John Reed	CA	Retina Specialist (Ophthalmology) Physician	$2.7M	$0
Robert Equi	CA	Retina Specialist (Ophthalmology) Physician	$2.7M	$0
Bradley Chipps	CA	Allergy Physician	$1.6M	$0
Mark Bowers	CA	Clinical Cardiac Electrophysiology Physician	$641.1K	$0
Arash Aryana	CA	Clinical Cardiac Electrophysiology Physician	$580.7K	$0

Sarju Patel — Billing Profile & Reimbursement Data

Sign up for Sarju Patel — Billing Profile & Reimbursement Data policy alerts

Sarju Patel — Billing Profile & Reimbursement Data

Sign up for Sarju Patel — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References